mTORC2 is required for proliferation and survival of TSC2-null cells

Molecular and Cellular Biology

Volumn 31, Issue 12, 2011, Pages 2484-2498

  Goncharova, Elena A ^a   Goncharov, Dmitry A ^a   Li, Hua ^a   Pimtong, Wittaya ^a   Lu, Stephen ^a   Khavin, Irene ^a   Krymskaya, Vera P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN BCL 2; PROTEIN KINASE B; PUMA PROTEIN; RAPAMYCIN; RHEB PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN; SMALL INTERFERING RNA; TUBERIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LEIOMYOMA; MONOTHERAPY; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TUMOR RECURRENCE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOPTOSIS; CARRIER PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, KNOCKOUT; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; SIMVASTATIN; SIROLIMUS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; RAPTORES;

EID: 79958068761     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01061-10     Document Type: Article

References (96)

1. Ahn, K. S., G. Sethi, and B. B. Aggarwal. 2008. Reversal of chemoresistance and enhancement of apoptosis by statins through down-regulation of the NF-κB pathway. Biochem. Pharmacol. 75, 907-913.
2. Aliabadi, A. Z., et al. 2008. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation. Transplantation 86, 1771-1776.
3. Bissler, J. J., et al. 2008. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140-151.
4. Blanco-Colio, L. M., et al. 2002. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161, 17-26.
5. Breuleux, M., et al. 2009. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8, 742-753.
6. Budman, D. R., J. Tai, and A. Calabro. 2007. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res. Treat. 104, 93-101.
7. Cafforio, P., F. Dammacco, A. Gernone, and F. Silvestris. 2005. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 26, 883-891.
8. Calabro, A., J. Tai, S. L. Allen, and D. R. Budman. 2008. In-vitro synergism of m-TOR inhibitors, statins, and classical chemotherapy, potential implications in acute leukemia. Anticancer Drugs 19, 705-712.
9. Castro, A. F., J. F. Rebhun, G. G. Clark, and L. A. Quilliam. 2003. Rheb binds TSC2 and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32493-32496.
10. Cho, S.-J., et al. 2008. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int. J. Cancer 123, 951-957.
11. Coleman, K., C. J. Marshal, and M. F. Olson. 2004. Ras and Rho GTPases in G1-phase cell-cycle regulation. Nat. Rev. Mol. Cell Biol. 5, 355-366.
12. Copp, J., G. Manning, and T. Hunter. 2009. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR), phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69, 1821-1827.
13. Costello, P. S., S. C. Cleverley, R. Galandrini, S. W. Henning, and D. A. Cantrell. 2000. The GTPase rho controls a p53-dependent survival checkpoint during thymopoiesis. J. Exp. Med. 192, 77-85.
14. Davies, D. M., et al. 2008. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N. Engl. J. Med. 358, 200-203.
15. Demierre, M.-F., P. D. R. Higgins, S. B. Gruber, E. Hawk, and S. M. Lippman. 2005. Statins and cancer prevention. Nat. Rev. Cancer 5, 930-942.
16. Etienne-Manneville, S., and A. Hall. 2002. Rho GTPases in cell biology. Nature 420, 629-635.
17. Ferri, N., et al. 2008. Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/ cyclin E expression. Mol. Pharmacol. 74, 144-153.
18. Finlay, G. A., et al. 2007. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res. 67, 9878-9886.
19. Fiorentini, C., et al. 1998. Toxin-induced activation of Rho GTP-binding protein increases Bcl-2 expression and influences mitochondrial homeostasis. Exp. Cell Res. 242, 341-350.
20. Foster, K. G., and D. C. Fingar. 2010. Mammalian Target of Rapamycin (mTOR), conducting the cellular signaling symphony. J. Biol. Chem. 285, 4071-14077.
21. Franz, D. N., et al. 2006. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59, 490-498.
22. Fromigué, O., et al. 2006. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42//p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 13, 1845- 1856.
23. Fuchs, D., C. Berges, G. Opelz, V. Daniel, and C. Naujokat. 2008. HMGCoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem. Biophys. Res. Commun. 374, 309-314.
24. Garami, A., et al. 2003. Insulin activation of Rheb, a mediator of mTOR/ S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11, 1457-1466.
25. Ghosh-Choudhury, N., C. C. Mandal, N. Ghosh-Choudhury, and G. Ghosh Choudhury. 2010. Simvastatin induces derepression of PTEN expression via NFκB to inhibit breast cancer cell growth. Cell. Signal. 22, 749-758.
26. Gómez, J., C. Martínez-A. M. Giry, A. García, and A. Rebollo. 1997. Rho prevents apoptosis through Bcl-2 expression, implications for interleukin-2 receptor signal transduction. Eur. J. Immunol. 27, 2793-2799.
27. Goncharova, E., D. Goncharov, D. Noonan, and V. P. Krymskaya. 2004. TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J. Cell Biol. 167, 1171-1182.
28. Goncharova, E. A., et al. 2008. Interferon β augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation. Mol. Pharmacol. 73, 778-788.
29. Goncharova, E. A., et al. 2009. STAT3 is required for abnormal proliferation and survival of TSC2-deficient cells, relevance to pulmonary LAM. Mol. Pharmacol. 76, 766-777.
30. Goncharova, E. A., et al. 2002. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation, a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277, 30958-30967.
31. Goncharova, E. A., D. A. Goncharov, P. N. Lim, D. Noonan, and V. P. Krymskaya. 2006. Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am. J. Respir. Cell Mol. Biol. 34, 473-480.
32. Goncharova, E. A., et al. 2006. Abnormal smooth muscle cell growth in lymphangioleiomyomatosis (LAM), role for tumor suppressor TSC2. Am. J. Respir. Cell Mol. Biol. 34, 561-572.
33. Goncharova, E. A., and V. P. Krymskaya. 2008. Pulmonary lymphangioleiomyomatosis (LAM), progress and current challenges. J. Cell. Biochem. 103, 69-382.
34. Goncharova, E. A., P. Lin, D. A. Goncharov, A. Eszterhas, R. A. Panettieri, Jr., and V. P. Krymskaya. 2006. Assays for in vitro monitoring proliferation of human airway smooth muscle (ASM) and human pulmonary arterial vascular smooth muscle (VSM) cells. Nat. Protoc. 1, 2905-2908.
35. Guertin, D. A., and D. M. Sabatini. 2009. The pharmacology of mTOR inhibition. Sci. Signal. 2, pe24.
36. Guertin, D. A., et al. 2006. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKC[alpha], but not S6K1. Dev. Cell 11, 859-871.
37. Harrington, L. S., et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166, 213-223.
38. Howe, S. R., et al. 1995. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol. 146, 1568-1579.
39. Hsu, S. Y., A. I. Kaipia, E. McGee, M. Lomeli, and A. J. W. Hsueh. 1997. Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. Proc. Natl. Acad. Sci. U. S. A. 94, 12401-12406.
40. Huang, J., C. C. Dibble, M. Matsuzaki, and B. D. Manning. 2008. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell. Biol. 28, 4104-4115.
41. Huynh, H., C. Teo, and K. Soo. 2007. Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol. Cancer Ther. , 2959-2966.
42. Hwang, K. E., et al. 13 May 2010. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest. New Drugs. [Epub ahead of print.] doi, 10.1007/s10637-010-9450-2.
43. Inoki, K., Y. Li, T. Xu, and K.-L. Guan. 2003. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 829- 1834.
44. Jacinto, E., et al. 2004. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122-1128.
45. Jaffe, A. B., and A. Hall. 2005. RHO GTPASES, biochemistry and biology. Annu. Rev. Cell Dev. Biol. 21, 247-269.
46. Johnson, S. R. 2006. Lymphangioleiomyomatosis. Eur. Respir. J. 27, 1056- 1065.
47. Karlsson, R., E. D. Pedersen, Z. Wang, and C. Brakebusch. 2009. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 1796, 91-98.
48. Katano, H., L. Pesnicak, and J. I. Cohen. 2004. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc. Natl. Acad. Sci. U. S. A. 101, 4960-4965.
49. Kawata, S., et al. 2001. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br. J. Cancer 84, 86-891.
50. Kenerson, H., T. A. Dundon, and R. S. Yeung. 2005. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr. Res. 57, 67-75.
51. Knudson, A. G. 2000. Chasing the cancer demon. Annu. Rev. Genet. 34, 1-19.
52. Kochuparambil, S. T., B. Al-Husein, A. Goc, S. Soliman, and P. R. Somanath. 2011. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and re-duced prostate-specific antigen expression. J. Pharmacol. Exp. Ther. 336, 496-505.
53. Kovarik, J. M., C. Hsu, L. McMahon, S. Berthier, and C. Rordorf. 2001. Population pharmacokinetics of everolimus in de novo renal transplant patients, impact of ethnicity and comedications. Clin. Pharmacol. Ther. 70, 247-254.
54. Krymskaya, V. P., and E. A. Goncharova. 2009. PI3K/mTORC1 activation in hamartoma syndromes, therapeutic prospects. Cell Cycle 8, 403-413.
55. Krymskaya, V. P., et al. 2 March 2011. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J. [Epub ahead of print.] doi, 10.1096/fj.10-175018.
56. Lamb, R. F., et al. 2000. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat. Cell Biol. 2, 81-287.
57. Laplante, M., and D. M. Sabatini. 2009. mTOR signaling at a glance. J. Cell Sci. 122, 3589-3594.
58. Laufs, U., D. Marra, K. Node, and J. K. Liao. 1999. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced down-regulation of p27Kip1. J. Biol. Chem. 274, 21926-21931.
59. Lee, L., P. Sudentas, and S. L. Dabora. 2006. Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex. Genes Chromosomes Cancer 45, 933-944.
60. Lee, L., et al. 2005. Efficacy of a rapamycin analog (CCI-779) and IFNgamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42, 213-27.
61. Lee, N., et al. 2009. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models. BMC Pharmacol. 9, 8.
62. Lennernäs, H., and G. Fager. 1997. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403-425.
63. Li, Y., M. N. Corradetti, K. Inoki, and K.-L. Guan. 2004. TSC2, filling the GAP in the mTOR signaling pathway. Trends Biochem. Sci. 29, 32-38.
64. Loewith, R., et al. 2002. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell 10, 457-468.
65. Long, X., S. Ortiz-Vega, Y. Lin, and J. Avruch. 2005. Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J. Biol. Chem. 280, 23433-23436.
66. Maeda, A., et al. 2010. Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis 208, 112-118.
67. Mahalati, K., and B. D. Kahan. 2001. Clinical pharmacokinetics of sirolimus. Clin. Pharmacokinet. 40, 573-585.
68. Messina, M. P., A. Rauktys, L. Lee, and S. L. Dabora. 2007. Tuberous sclerosis preclinical studies, timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol. 7, 14.
69. Murgia, M. G., S. Jordan, and B. D. Kahan. 1996. The side effect profile of sirolimus, a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int. 49, 209-216.
70. Murtola, T. J., T. Visakorpi, J. Lahtela, H. Syvala, and T. L. J. Tammela. 2008. Statins and prostate cancer prevention, where we are now, and future directions. Nat. Clin. Pract. Urol. 5, 376-387.
71. Nonaka, M., et al. 2009. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. Exp. Cell Res. 315, 141-150.
72. Pollizzi, K., I. Malinowska-Kolodziej, M. Stumm, H. Lane, and D. Kwiatkowski. 2009. Equivalent benefit of mTORC1 blockade and combined PI3KmTOR blockade in a mouse model of tuberous sclerosis. Mol. Cancer 8, 38.
73. Rattan, R., S. Giri, A. K. Singh, and I. Singh. 2006. Rho/ROCK pathway as a target of tumor therapy. J. Neurosci. Res. 83, 243-255.
74. Sahai, E., and C. J. Marshal. 2002. Rho-GTPases and cancer. Nat. Rev. Cancer 2, 133-142.
75. Sarbassov, D. D., et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14, 1296-1302.
76. Schmelzle, T., and M. N. Hall. 2000. TOR, a central controller of cell growth. Cell 103, 253-262.
77. Schmidt, A., M. Bickle, T. Beck, and M. N. Hall. 1997. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell 88, 531-542.
78. Schonder, K. S., T. P. McKaveney, and K. J. Lynch. 2005. Retrospective analysis of hyperlipidemia management in a transplant population. harmacotherapy 25, 918-923.
79. Schoonjans, K., et al. 1999. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett. 452, 160-164.
80. Shah, O. J., Z. Wang, and T. Hunter. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14, 1650-1656.
81. Shiota, C., J. Woo, J. Lindner, K. D. Shelton, and M. A. Magnuson. 2006. Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev. Cell 11, 583-589.
82. Soliman, G. A., et al. 2010. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J. Biol. Chem. 285, 7866-7879.
83. Sun, S. Y., et al. 2005. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65, 052-7058.
84. Takeda, N., et al. 2006. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin. Am. J. Respir. Cell Mol. iol. 35, 722-729.
85. Taveira-DaSilva, A. M., and J. Moss. 2006. Lymphangioleiomyomatosis. Cancer Control 13, 276-285.
86. Thibault, A., et al. 1996. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin. Cancer Res. 2, 483-491.
87. Torrance, C. J., V. Agrawal, B. Vogelstein, and K. W. Kinzler. 2001. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19, 940-945.
88. Um, S. H., et al. 2004. Absence of S6K1 protects against age- and dietinduced obesity while enhancing insulin sensitivity. Nature 431, 200-205.
89. Vaughan, C. J., and A. M. Gotto, Jr. 2004. Update on statins, 2003. Circulation 110, 886-892.
90. von Tresckow, B., et al. 2007. Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. Haematologica 92, 682-685.
91. Wong, W. W., J. Dimitroulakos, M. D. Minden, and L. Z. Penn. 2002. HMG-CoA reductase inhibitors and the malignant cell, the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16, 508-519.
92. Wu, J., W. W. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn. 2004. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 64, 6461-6468.
93. Yeung, R. S. 2003. Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 38, 368-375.
94. Zhang, H., et al. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223-233.
95. Zhang, Y., et al. 2003. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5, 578-581.
96. Zimmerman, J. J. 2004. Exposure-response relationships and drug interactions of sirolimus. AAPS J. 6, e28.